Telomir Pharmaceuticals Inc is a preclinical-stage biotechnology company focused on the development of small-molecule therapeutics designed to address upstream biological drivers of aging and age-related diseases rather than treating symptoms alone. The company's research targets fundamental cellular processes associated with disease progression and functional decline, including metal-ion dysregulation, oxidative stress, epigenetic regulation, mitochondrial dysfunction, and telomere integrity. Telomir's investigational compound, Telomir-1 (Zn-Telomir), is a novel orally administered small molecule engineered to modulate intracellular metal balance particularly iron, copper, calcium, and zinc.
Last trade$0.4816
Day change+$0.0006 (+0.12%)
Day range$0.42 – $0.505
Volume295,855
Market cap$35M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$35.36M
Price / earnings
—
Price / book
8.03×
Price / sales
—
EV / sales
—
EV / EBITDA
-5.44×
Profitability
Earnings per share
-$0.70
Return on assets
-1,111.59%
Return on equity
-1,171.34%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.02×
Current ratio
19.6×
Quick ratio
19.6×
Cash ratio
19.07×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.57M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for TELO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$493.31K
$1.32M
$573.54K
$838.47K
$386.95K
$5.03M
$1.85M
$2.64M
Research and development
$251.89K
$444.67K
$467.8K
$1.3M
$759.53K
$42.84K
$337K
$269.08K
Total operating expenses
$745.2K
$1.76M
$1.04M
$2.13M
$1.15M
$5.07M
$2.19M
$2.91M
Operating income
-$745.2K
-$1.76M
-$1.04M
-$2.13M
-$1.15M
-$5.07M
-$2.19M
-$2.91M
Interest expense
-$1.91K
-$3.03K
-$1.26K
$1.39K
$0
-$1.34K
-$46
$1
Income before taxes
-$705.23K
-$1.72M
-$990.95K
-$2.06M
-$1.1M
-$5.07M
-$2.18M
-$2.9M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$705.23K
-$1.72M
-$990.95K
-$2.06M
-$1.1M
-$5.07M
-$2.18M
-$2.9M
Net income attributable to common shareholders
-$705.23K
-$47.84M
-$990.95K
-$2.06M
-$1.1M
-$5.07M
-$2.18M
-$2.9M
EBITDA
-$745.2K
-$1.76M
-$1.04M
-$2.13M
-$1.15M
-$5.07M
-$2.19M
-$2.91M
Basic earnings per share
-$0.01
-$0.79
-$0.03
-$0.06
-$0.03
-$0.17
-$0.07
-$0.10
Diluted earnings per share
-$0.01
-$0.79
-$0.03
-$0.06
-$0.03
-$0.17
-$0.07
-$0.10
Recent news
Company coverage with links to the original publishers.
U.S. stock futures fell on Tuesday, with market attention focused on potential Federal Reserve rate cuts and ongoing government shutdown. Key companies like AMD and Trilogy Metals saw significant stock movements due to strategic developments.
TAMPA, Fla., July 02, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq: TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and commercialization of Telomir-1 as the first novel small molecule to lengthen the DNA’s protective telomere caps as a potential treatment for age-related conditions, today announced that the Company has been added as a member of the broad-market Russell 3000® and the Russell Microcap® Indexes, effective July 1, as part of the 2024 Russell indexes reconstitution.
Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products Drug Information Association (DIA) 2024 is the largest global, multidisciplinary event for the professionals involved in the discovery, development, and lifecycle management of pharmaceuticals, biotechnology, medical devices, and related products
Commences the study, The Safety of Telomir-1 when Administered Orally to Geriatric Laboratory Beagle Dogs for 63 Consecutive Days study to evaluate the safety of Telomir-1 on geriatric canines
Telomir-1 elongates telomere caps on human normal embryonic fibroblast cells by stimulating the enzyme telomerase that protects the DNA and genetic material in chromosomes to combat aging
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.